Biotricity downgraded to Neutral from Buy at H.C. Wainwright

H.C. Wainwright analyst Kevin Dede downgraded Biotricity to Neutral from Buy without a price target. The company needs to demonstrate sales acceleration, perhaps significant enough as a function of its mathematical derivative, in engendering investor interest, the analyst tells investors in a research note. The firm says it is now more comfortable on the sidelines post the fiscal Q2 report.